Davis Glenn Eugene 4
4 · ISTA PHARMACEUTICALS INC · Filed Jun 15, 2012
Insider Transaction Report
Form 4
Davis Glenn Eugene
VP Legal & Chief Comp. Officer
Transactions
- Disposition to Issuer
Common Stock
2012-06-06$9.10/sh−29,205$265,766→ 0 total - Disposition to Issuer
Option (right to buy)
2012-06-06+13,500→ 0 totalExercise: $5.44Exp: 2021-01-28→ Common Stock (13,500 underlying) - Disposition to Issuer
Option (right to buy)
2012-06-06+60,000→ 0 totalExercise: $1.52Exp: 2019-03-01→ Common Stock (60,000 underlying) - Disposition to Issuer
Option (right to buy)
2012-06-06+33,750→ 0 totalExercise: $3.75Exp: 2021-11-30→ Common Stock (33,750 underlying) - Disposition to Issuer
Option (right to buy)
2012-06-06+13,500→ 0 totalExercise: $3.63Exp: 2020-02-02→ Common Stock (13,500 underlying)
Footnotes (5)
- [F1]Disposed of pursuant to agreement and plan of merger by and among the Company, Bausch & Lomb Incorporated and Inga Acquisition Corporation, as amended (the "Merger Agreement") in exchange for $9.10 per share, without interest, less any applicable withholding tax, on the effective date of the merger.
- [F2]The option which was unvested was cancelled in the Merger Agreement in exchange for a cash payment equal to $5.35 per share (representing the difference between the exercise price of the option and the merger consideration of $9.10).
- [F3]The option which had 4,500 options vested and 9,000 unvested options was cancelled in the Merger Agreement in exchange for a cash payment equal to $3.66 per share (representing the difference between the exercise price of the option and the merger consideration of $9.10).
- [F4]The option which had 7,593 options vested and 5,907 unvested options was cancelled in the Merger Agreement in exchange for a cash payment equal to $5.47 per share (representing the difference between the exercise price of the option and the merger consideration of $9.10).
- [F5]The option which had 47,500 options vested and 12,500 unvested options was cancelled in the Merger Agreement in exchange for a cash payment equal to $7.58 per share (representing the difference between the exercise price of the option and the merger consideration of $9.10).